Singapore consults on major revisions to drug registration procedures
This article was originally published in SRA
Executive Summary
Singapore's Health Sciences Authority has proposed substantial changes to its guidance on the registration of human medicinal products to incorporate, among other things, a new chapter on the registration of biosimilar products and a new fast-track procedure for evaluating generic drug applications1,2.